BioCryst Pharmaceuticals | BCRX - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Chugai Pharma JPY 1.65B 50K 2026-03
Daiichi Sankyo JPY 1.85B 9K 2025-12
DBV Technologies USD 235.6M 98.78M 2025-12
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2026-03
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Glaxosmithkline GBP 4.05B 20.6M 2026-03
Incyte USD 199.95M 1.49M 2026-03
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Neurocrine Biosciences USD 100.6M 500K 2026-03
Novavax USD 162.58M 106K 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 105.57M 607K 2026-03
Ultragenyx Pharmaceutical USD 98.3M 1.7M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03